Prediction of thyroidal  131 I effective half-life in patients with Graves’ disease

Ruiguo Zhang; Guizhi Zhang; Renfei Wang; Jian Tan; Yajing He; Zhaowei Meng

doi:10.18632/oncotarget.20849

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prediction of thyroidal ¹³¹I effective half-life in patients with Graves’ disease

Ruiguo Zhang, Guizhi Zhang, Renfei Wang, Jian Tan _, Yajing He and Zhaowei Meng

PDF | HTML | How to cite

Oncotarget. 2017; 8:80934-80940. https://doi.org/10.18632/oncotarget.20849

Metrics: PDF 1398 views | HTML 2457 views | ?

Abstract

Ruiguo Zhang1, Guizhi Zhang1, Renfei Wang1, Jian Tan1, Yajing He1 and Zhaowei Meng1

1Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China

Correspondence to:

Jian Tan, email: [email protected]

Keywords: Graves’ disease, effective half-life, radioiodine therapy, iodine uptake, predictive model

Received: June 27, 2017 Accepted: August 07, 2017 Published: September 12, 2017

ABSTRACT

Purpose: Calculation of effective thyroidal half-life (Teff) of iodine-131(¹³¹I) is cumbersome and tedious. The aim of this study was to investigate factors that could be used to predict Teff and to develop a Teff prediction model in Graves’ disease patients.

Methods: A total of 256 patients with GD were involved in this study. We investigated the influences of age, gender, disease duration, thyroid weight, antithyroid drugs, antithyroid drugs discontinuation period (ADP), thyroid function indexes, thyroid autoantibodies, thyroid-stimulating hormone receptor antibody (TRAb) level and radioactive iodine uptake (RAIU) values before ¹³¹I therapy on Teff, applying univariate and multivariate analyses.

Results: Teff correlated negatively with thyroid peroxidase antibody, TRAb and thyroid weight, as well as positively with 24-hour, 48-hour, and 72-hour RAIU. Additionally, a longer ADP (especially≥ 14d) or without antithyroid drugs before ¹³¹I therapy led to a longer Teff. Stepwise multiple linear regression analysis showed that 24-hour and 72-hour RAIU were statistically significant predictors of Teff (P<0.001). The relationship was: predictive Teff=5.277+0.295×72-hour RAIU-0.217×24-hour RAIU (r =0.865, P < 0.001).

Conclusion: The present results indicate that prediction of Teff from 24-hour and 72-hour RAIU is feasible in patients with Graves’ disease, with high prediction accuracy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20849

Publication Alerts

Research Papers:

Prediction of thyroidal 131I effective half-life in patients with Graves’ disease

Abstract

Prediction of thyroidal ¹³¹I effective half-life in patients with Graves’ disease